CGEN Stock Analysis: Buy, Sell, or Hold?
CGEN - Compugen Ltd
$2.38
0.03 (1.28%)
▲
5d:
+0.0%
30d:
+4.39%
90d:
-12.18%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 03, 2026
0d
Get Alerted When CGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CGEN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CGEN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CGEN is currently trading at $2.38, which is considered slightly high relative to its 30-day fair value range of $2.20 to $2.42.
Technical Outlook: Technically, CGEN is showing sideways momentum. Immediate support is located at $2.17, while resistance sits at $2.52.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (11th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $4.60 (+95.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CGEN is showing sideways momentum. Immediate support is located at $2.17, while resistance sits at $2.52.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (11th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $4.60 (+95.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.20 -
$2.42
Company Quality Score
52/100
(HOLD)
Options IV Signal
11th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
73.8%
All Signals
- BULLISH: Options cheap (IV 11th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 95.7% below Wall St target ($4.60)
Trading Range Analysis
30-Day Trading Range
$2.20 -
$2.42
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.22
(9.4%)
Support & Resistance Levels
Support Level
$2.17
Resistance Level
$2.52
Current Trend
Sideways
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.44
Wall Street Target
$4.60
(+95.7%)
Revenue Growth (YoY)
-4.7%
Profit Margin
48.0%
Share & Embed Analysis
Last updated: August 03, 2026 3:53 PM ET
Data refreshes hourly during market hours. Next update: 4:53 PM
Data refreshes hourly during market hours. Next update: 4:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Eran Ophir
SELL
5000 shares
2026-04-14
Zurit Levine
SELL
3125 shares
2026-04-10
Zurit Levine
SELL
5375 shares
2026-04-08
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$123 | 59 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 54 HOLD |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 60 HOLD |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
13 analysts |
$108 | 60 BUY |
